On February 8, 2024, Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of an underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares at a purchase price of $4.499 per pre-funded warrant. Tenaya anticipates gross proceeds from the offering to be approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction.

Leerink Partners and TD Cowen acted as joint book running managers for the offering. LifeSci Capital acted as lead manager for the offering.

The Wilson Sonsini team that advised Tenaya Therapeutics in the offering included Jennifer Knapp, James Babikian, Tamara Labanowski, Erica Wolfe Heinz, Michael Hostetler, and Derrick Rowe.

For more information, please see Tenaya Therapeutics’ news release.